Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bristol-Myers Squibb has paid $175 million in cash, with the promise of up to $550 million in milestones, to acquire privately held iPierian. With the deal, BMS gains the rights to IPN007, an antibody aimed at progressive supranuclear palsy (PSP) and other neurodegenerative diseases associated with the buildup of tau, a protein believed to help regulate the activity of brain cells. IPN007 is expected to enter Phase I studies in early 2015 as a treatment for PSP, but it has the potential to be useful in treating Alzheimer’s disease.
This article has been sent to the following recipient: